Loading...

Bavarian Nordic A/S

BVNKFPNK
Healthcare
Biotechnology
$37.20
$0.00(0.00%)

Bavarian Nordic A/S (BVNKF) Financial Performance & Income Statement Overview

View comprehensive annual and quarterly summaries for Bavarian Nordic A/S (BVNKF), featuring income statements, balance sheets, and cash flow data.

Revenue Growth
-19.06%
19.06%
Operating Income Growth
-37.25%
37.25%
Net Income Growth
-33.03%
33.03%
Operating Cash Flow Growth
74.22%
74.22%
Operating Margin
20.40%
20.40%
Gross Margin
51.90%
51.90%
Net Profit Margin
21.20%
21.20%
ROE
11.99%
11.99%
ROIC
10.82%
10.82%

Bavarian Nordic A/S (BVNKF) Income Statement & Financial Overview

Explore comprehensive income reports for Bavarian Nordic A/S BVNKF, broken down by year and quarter.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$1.35B$2.09B$1.36B$1.43B
Cost of Revenue$665.95M$839.90M$783.76M$707.55M
Gross Profit$680.64M$1.25B$579.60M$719.95M
Gross Profit Ratio$0.51$0.60$0.43$0.50
R&D Expenses$172.11M$203.54M$264.28M$209.59M
SG&A Expenses$249.65M$341.24M$221.75M$244.47M
Operating Expenses$421.76M$544.77M$486.03M$454.06M
Total Costs & Expenses$1.09B$1.38B$1.27B$1.16B
Interest Income$7.69M$12.59M$9.36M$9.55M
Interest Expense$2.80M$4.34M$3.65M$2.44M
Depreciation & Amortization$160.66M$163.63M$156.89M$153.65M
EBITDA$396.27M$921.91M$252.84M$441.03M
EBITDA Ratio$0.29$0.44$0.19$0.31
Operating Income$258.89M$709.20M$93.57M$265.89M
Operating Income Ratio$0.19$0.34$0.07$0.19
Other Income/Expenses (Net)-$29.34M$37.85M-$21.11M$97000.00
Income Before Tax$229.55M$747.05M$72.46M$265.99M
Income Before Tax Ratio$0.17$0.36$0.05$0.19
Income Tax Expense$10.79M-$23.76M$1.97M$4.86M
Net Income$218.76M$770.81M$70.49M$261.13M
Net Income Ratio$0.16$0.37$0.05$0.18
EPS$2.70$9.84$0.90$3.30
Diluted EPS$2.70$9.84$0.90$3.30
Weighted Avg Shares Outstanding$81.02M$78.57M$78.32M$79.13M
Weighted Avg Shares Outstanding (Diluted)$81.02M$78.57M$78.32M$79.13M

Over the past four quarters, Bavarian Nordic A/S demonstrated steady revenue growth, increasing from $1.43B in Q2 2024 to $1.35B in Q1 2025. Operating income reached $258.89M in Q1 2025, maintaining a consistent 19% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $396.27M, reflecting operational efficiency. Net income dropped to $218.76M, with EPS at $2.70. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;